论文部分内容阅读
目的:观察利拉鲁肽治疗口服降糖药治疗糖尿病效果不佳患者的疗效并观察其对患者体重、收缩压等指标的影响。方法:完全随机法将76例患者分成利拉鲁肽组和甘精胰岛素组,在使用原有口服降糖药的基础上,首先停用或者减量除二甲双胍之外的降糖药物,利拉鲁肽组加用利拉鲁肽,起始0.6 mg·d-1,1周后增至1.2 mg·d-1,每天固定时间一次,甘精胰岛素组皮下注射甘精胰岛素,每日睡前皮下注射,起始剂量为0.1~0.2 U·kg-1·d-1,治疗12周时复查FBG、HbA1c和收缩压、腰围(WC)、臀围(HC)等指标。结果:2组患者的FBG、HbA1c、2hBG均较入院前化验指标明显下降(P<0.05),但A组和B组比较无统计学意义(P>0.05);BMI、收缩压、WC、HC方面,2组比较,差异具有统计学意义(P<0.05),B组与治疗前比较,差异不明显(P>0.05)。结论:利拉鲁肽可以降低口服降糖药效果不佳的2型糖尿病患者的血糖,发生低血糖的机率低,且可以改善患者的β细胞功能、收缩压和体质量。
OBJECTIVE: To observe the curative effect of liraglutide on oral hypoglycemic agents in patients with poor response to diabetes and observe its effects on body weight and systolic blood pressure. Methods: Randomly divided 76 patients into liraglutide group and insulin glargine group, based on the use of the original oral hypoglycemic agents, first disable or reduce the antidiabetic drugs other than metformin, Hydrupeptide group with liraglutide, starting 0.6 mg · d-1,1 weeks and then increased to 1.2 mg · d-1, fixed time once a day, insulin glargine subcutaneous injection of insulin glargine, daily subcutaneous injection before going to bed , The initial dose of 0.1 ~ 0.2 U · kg-1 · d-1, FBG, HbA1c and systolic blood pressure, waist circumference (WC), hip circumference (HC) Results: FBG, HbA1c and 2hBG in both groups were significantly lower than those before admission (P <0.05), but there was no significant difference between group A and group B (P> 0.05); BMI, systolic blood pressure, In the two groups, the difference was statistically significant (P <0.05). There was no significant difference between group B and before treatment (P> 0.05). Conclusion: Liraglutide can reduce the blood sugar, the incidence of hypoglycemia in patients with type 2 diabetes who are not good oral hypoglycemic agents, and can improve the β-cell function, systolic blood pressure and body mass in patients.